Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Istinye University Liv Hospital

1 abstract

Abstract
Quantitative circulating tumor DNA (ctDNA) assessment in patients (pts) with advanced urothelial carcinoma (UC) treated with pembrolizumab (pembro) or platinum-based chemotherapy (chemo) from the phase 3 KEYNOTE-361 trial.
Org: Yamaguchi University Hospital, Fundación Arturo López Pérez, Fred Hutchinson Cancer Center and University of Washington, Life Groenkloof Hospital, Istinye University Liv Hospital,